StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc. (ALNY) stock

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3049% below fair value
$149.40−7.10 (-4.54%)

Close on Nov 18, 2026Market cap $20.01BP/E 7.8Yield –

Alnylam Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Alnylam Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was $977.59M, up 269.3% year over year. For fiscal 2025 it was $501.58M. The highest annual figure on record is $501.58M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$501.58M–
FY2024Dec 31, 2024-$176.89M–
FY2023Dec 31, 2023-$282.18M–
FY2022Dec 31, 2022-$785.07M–
FY2021Dec 31, 2021-$708.65M–
FY2020Dec 31, 2020-$828.44M–
FY2019Dec 31, 2019-$939.43M–
FY2018Dec 31, 2018-$814.67M–
FY2017Dec 31, 2017-$500.09M–
FY2016Dec 31, 2016-$424.59M–
FY2015Dec 31, 2015-$296.01M–
FY2014Dec 31, 2014-$404.98M–
FY2013Dec 31, 2013-$92.94M–
FY2012Dec 31, 2012-$129.46M–
FY2011Dec 31, 2011-$54.82M–
FY2010Dec 31, 2010-$44.07M–
FY2009Dec 31, 2009-$48.11M–
FY2008Dec 31, 2008-$27.84M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$345.80M-6.0%
Q2 FY2026Jun 30, 2026$231.44M–
Q1 FY2026Mar 31, 2026$268.64M+1386.1%
Q4 FY2025Dec 31, 2025$131.72M–
Q3 FY2025Sep 30, 2025$367.98M–
Q2 FY2025Jun 30, 2025-$16.20M-133.3%
Q1 FY2025Mar 31, 2025$18.08M–
Q4 FY2024Dec 31, 2024-$105.16M–
Q3 FY2024Sep 30, 2024-$76.91M-136.0%
Q2 FY2024Jun 30, 2024$48.61M–
Q1 FY2024Mar 31, 2024-$43.44M–
Q4 FY2023Dec 31, 2023-$116.40M–
Q3 FY2023Sep 30, 2023$213.87M–
Q2 FY2023Jun 30, 2023-$229.83M–
Q1 FY2023Mar 31, 2023-$149.81M–
Q4 FY2022Dec 31, 2022-$188.61M–
Q3 FY2022Sep 30, 2022-$258.04M–
Q2 FY2022Jun 30, 2022-$191.69M–
Q1 FY2022Mar 31, 2022-$146.73M–
Q4 FY2021Dec 31, 2021-$194.56M–
Q3 FY2021Sep 30, 2021-$181.68M–
Q2 FY2021Jun 30, 2021-$146.16M–
Q1 FY2021Mar 31, 2021-$186.25M–
Q4 FY2020Dec 31, 2020-$194.22M–
Q3 FY2020Sep 30, 2020-$225.20M–
Q2 FY2020Jun 30, 2020-$198.86M–
Q1 FY2020Mar 31, 2020-$210.16M–
Q4 FY2019Dec 31, 2019-$298.07M–
Q3 FY2019Sep 30, 2019-$216.30M–
Q2 FY2019Jun 30, 2019-$236.27M–
Q1 FY2019Mar 31, 2019-$188.79M–
Q4 FY2018Dec 31, 2018-$220.36M–
Q3 FY2018Sep 30, 2018-$254.56M–
Q2 FY2018Jun 30, 2018-$192.35M–
Q1 FY2018Mar 31, 2018-$147.41M–
Q4 FY2017Dec 31, 2017-$147.30M–
Q3 FY2017Sep 30, 2017-$125.80M–
Q2 FY2017Jun 30, 2017-$120.47M–
Q1 FY2017Mar 31, 2017-$106.51M–
Q4 FY2016Dec 31, 2016-$115.43M–

More Alnylam Pharmaceuticals figures

See a number that looks wrong?